Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Dasatinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL).

NCT02888990 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.

NCT NCT02888990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02888990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Dasatinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL).
Lead sponsor
Versailles Hospital
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
January 31, 2016
Enrollment
71 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoblastic, acute